Interventional Oncology Gains Momentum with Quantum Surgical Deal

Medtech deal activity continues to move quickly, and the latest transaction highlights growing momentum in interventional oncology.

This week, Quantum Surgical acquired NeuWave Medical from Johnson & Johnson. Financial terms were not disclosed, but the strategic implications are clear. Quantum Surgical’s expertise in robotic assistance and navigation will now be combined with NeuWave’s Microwave Ablation System under a new organization called Precision IO Group.

The company will be led by Kurt Azarbarzin, a medtech executive whose background includes leadership roles at Verb Surgical, EndoQuest Robotics, and SurgiQuest.

For Johnson & Johnson, the transaction reflects continued efforts to streamline its portfolio and concentrate on higher-growth segments. For Quantum Surgical, the acquisition provides both a proven technology platform and direct access to a large installed base of leading cancer centers.

To understand why the deal matters, it helps to look at the underlying market data.

The Numbers Behind Interventional Oncology Growth

Johnson & Johnson acquired NeuWave Medical in 2016, but the company had recently planned to discontinue the business as part of a broader strategic refocusing around core divisions.

Despite that decision, the technology has established a meaningful clinical footprint. Since 2011, NeuWave systems have been used to treat more than 100,000 patients with challenging lung, kidney, and liver solid tumors.

Today, the serviceable market for these procedures is estimated at roughly 150,000 to 200,000 global cases annually. While that number may appear relatively modest, the epidemiology suggests a much larger long-term opportunity, with ~300,000+ new cases each year in the U.S. 

Annual U.S. incidence, by tumor type:

• Liver (HCC & Metastatic) ~42,000
• Lung (NSCLC/Meta) ~229,000
• Kidney (RCC) ~80,000

And while not a primary diagnosis, there are also roughly 280,000 patients with secondary bone metastases who need pain palliation, which can be addressed with NeuWave’s technology.

Historically, energy-based tumor ablation has often been considered a last-resort treatment. Technological advancements are enabling this to transition to a fourth pillar in cancer treatment, and a first-line treatment for any patients who qualify.

NeuWave is currently the market leader for microwave ablation in interventional oncology. The platform is estimated to account for roughly 60% to 70% of the U.S. market and is used in approximately 70% of leading cancer centers nationwide.

This installed base may be the most valuable part of the acquisition.

By acquiring NeuWave, Precision IO gains immediate access to these hospital accounts, which could accelerate adoption of Quantum Surgical’s Epione robotic-assisted platform.

Platform Control and Procedure Growth

As we’ve previously discussed, success and market share are dependent on controlling the approach. The Epione robot provides all of the advantages necessary to increase procedure growth.

The system enables physicians to reach difficult tumors with sub millimeter precision. For some patients, that level of accuracy determines whether treatment is possible at all.

Robotic needle placement also helps standardize procedures. Hospitals and ambulatory surgery centers can reduce variability between operators, allowing less experienced physicians to perform cases more consistently.

Competitive Technologies Are Advancing Quickly

The broader market is also seeing rapid innovation from companies pursuing alternative energy-based approaches.

HistoSonics, for example, developed a noninvasive robotic histotripsy platform that is seeing early adoption in major U.S. cancer centers, initially focused on liver tumors. Investor enthusiasm has been strong. The company was acquired by a consortium of investors for $2.25 billion and later raised an additional $250 million.

Another emerging player is Galvanize Therapeutics, which uses pulsed electric field technology to treat tumors near sensitive areas in the lungs and other soft tissue. The company raised $100 million in September 2025 with support from several prominent investors and strategics, including Intuitive Surgical.

Unlike traditional ablation systems, these approaches rely on non-thermal energy. Heat-based technologies have historically faced limitations related to collateral tissue damage.

NeuWave’s microwave system addresses some of those concerns through a proprietary heating technology that radiates energy directly into tumor cells. Other differentiating features include Tissue-Loc to prevent probe migration as the patient moves, Active CO2 Cooling, and Multi-Probe Synchrony that allows multiple probes to operate simultaneously.

The platform also includes ABLATE-IQ software for pre-operative planning, perioperative ablation temperature monitoring, and confirmation that ablation margins fully cover the tumor.

Looking Ahead

Large medtech companies have spent the past several years narrowing their portfolios and concentrating resources on priority segments. As a result, technologies that may no longer fit within large corporate strategies are finding new opportunities with smaller companies that can focus entirely on their development.

NeuWave appears to be entering that type of second phase.

By combining NeuWave’s market access with Quantum Surgical’s robotic platform, Precision IO now has the ingredients to compete more aggressively in interventional oncology.

Platform plus clinical access can be a powerful combination, and it may position Precision IO to play a meaningful role as the field continues to expand.